TY - JOUR
T1 - 99mtc-labelled human serum transferrin for tumour imaging
T2 - an in vitro and in vivo study of the complex
AU - Smith, Tim A.D.
AU - Perkins, Alan C.
AU - Walton, Paul H.
PY - 2004/1/1
Y1 - 2004/1/1
N2 - This pilot study reports the uptake of 99mTc-transferrin by MCF7 cells and the biodistribution of the complex in mice bearing MCF7 tumours. Human serum holo-transferrin was labelled with 99mTc using pre-reduction with 2-mercaptoethanol. The uptake of the complex by MCF7 breast tumour cells, which was found to be competitively inhibited by the presence of unlabelled transferrin, reached a plateau within 30舁min. Two groups of xenografted mice with small and large tumours, respectively, were injected with the complex, and the uptake was followed for up to 24舁h post-administration using a dedicated gamma camera. The mean tumour uptake values, determined after dissection, in the two groups of mice were 6% (small tumours) and 1.7% (large tumours) of the injected dose per gram of tissue, with mean tumour/blood ratios of 2.7 and 1.7, respectively.
AB - This pilot study reports the uptake of 99mTc-transferrin by MCF7 cells and the biodistribution of the complex in mice bearing MCF7 tumours. Human serum holo-transferrin was labelled with 99mTc using pre-reduction with 2-mercaptoethanol. The uptake of the complex by MCF7 breast tumour cells, which was found to be competitively inhibited by the presence of unlabelled transferrin, reached a plateau within 30舁min. Two groups of xenografted mice with small and large tumours, respectively, were injected with the complex, and the uptake was followed for up to 24舁h post-administration using a dedicated gamma camera. The mean tumour uptake values, determined after dissection, in the two groups of mice were 6% (small tumours) and 1.7% (large tumours) of the injected dose per gram of tissue, with mean tumour/blood ratios of 2.7 and 1.7, respectively.
KW - Tc-transferrin
KW - Biodistribution
KW - Tumour targeting
UR - http://www.scopus.com/inward/record.url?scp=2142643738&partnerID=8YFLogxK
U2 - 10.1097/00006231-200404000-00012
DO - 10.1097/00006231-200404000-00012
M3 - Article
C2 - 15097814
AN - SCOPUS:2142643738
SN - 0143-3636
VL - 25
SP - 387
EP - 391
JO - NUCLEAR MEDICINE COMMUNICATIONS
JF - NUCLEAR MEDICINE COMMUNICATIONS
IS - 4
ER -